Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Or

Showing results (251-260 of 256) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 256 results.
Blood|February 3, 1998
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseasesS Slavin, A Nagler, E Naparstek, et al.
Blood|December 1, 1996
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotypeD Ben-Yehuda, S Krichevsky, O Caspi, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|January 11, 2007
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow TransplantationM Miano, M Labopin, O Hartmann, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Pageof 26

Showing results (251-260 of 256) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 256 results.
Blood|February 3, 1998
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseasesS Slavin, A Nagler, E Naparstek, et al.
Blood|December 1, 1996
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotypeD Ben-Yehuda, S Krichevsky, O Caspi, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|January 11, 2007
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow TransplantationM Miano, M Labopin, O Hartmann, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Pageof 26